JY
ALZN icon

Jeff Yass’s Alzamend Neuro ALZN Stock Holding History

Jeff Yass’s Portfolio ALZN Stock Details ALZN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-99
Closed -$57.5K – 11981
2023
Q1 		$57.5K Sell
99
-49
-33% -$36.8K ﹤0.01% 11632
2022
Q4 		$112K Sell
148
-92
-38% -$133K ﹤0.01% 10852
2022
Q3 		$386K Buy
240
+200
+500% +$275K ﹤0.01% 9144
2022
Q2 		$46K Buy
40
+26
+186% +$33.7K ﹤0.01% 12021
2022
Q1 		$23K Sell
14
-7
-33% -$13.1K ﹤0.01% 12579
2021
Q4 		$55K Buy
+21
New +$65K ﹤0.01% 12494

Other funds holding ALZN

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
Truist Financial
Truist Financial Charlotte, North Carolina $83.7B AUM 27.22% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
VF
Virtu Financial New York $3.18B AUM 65.92% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Jeff Yass's ALZN Position: Q4 2024 in Review

Jeff Yass sold out of Alzamend Neuro (ALZN) in Q4 2024, closing a stake of 1,845 shares — an estimated $28.1K sold.

Jeff Yass first reported a position in ALZN in Q2 2021 and held it in 8 quarters. The position peaked at $498K in Q2 2021. 14 funds tracked by Wall St. Rank hold ALZN as of Q4 2024.

  • Jeff Yass reported no remaining Alzamend Neuro position as of Q4 2024 after selling out during the quarter.
  • Jeff Yass sold 1,845 Alzamend Neuro shares in Q4 2024, an estimated $28.1K.
  • Jeff Yass first reported a position in Alzamend Neuro in Q2 2021 and held it in 8 quarters.
  • Jeff Yass's Alzamend Neuro position peaked at $498K in Q2 2021.
  • 14 funds tracked by Wall St. Rank held Alzamend Neuro as of Q4 2024.

Based on Susquehanna International Group's 13F filing for Q4 2024, filed 14 Feb 2025.